Topic hub · Metabolic science
Retatrutide research, all in one place.
Every retatrutide article and guide we have published — the phase 1 and phase 2 trials, the triple-agonist mechanism, safety signals, liver data and the questions the research has not answered yet. Each piece links to the underlying studies.
Educational only. Retatrutide is an investigational drug; nothing here is medical advice, a dosing protocol, or an endorsement of any product or supplier.
Start with the guides
New to retatrutide? These three reads take you from the basics to the full trial literature.
Retatrutide research: what the trials have actually shown
A long read through the published retatrutide research: the phase 1 and phase 2 trials, the triple-agonist mechanism, safety signals, the phase 3 programme and the gaps the data cannot fill.
What is retatrutide?
The investigational triple agonist behind the largest weight reductions ever reported in a metabolic trial: how it works, what the phase 2 data showed, and what is still unknown.
What is GLP-1?
The gut hormone behind the biggest story in metabolic medicine — the pathway retatrutide activates alongside GIP and glucagon receptors.
Retatrutide and GLP-1 articles
Research write-ups mentioning retatrutide, GLP-1 and the wider incretin class, newest first.
Get the weekly research dispatch
One email. New peer-reviewed research, distilled. No spam, unsubscribe in one click.